Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in sars-covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia vitt with cerebral sinus venous and portal vein thrombosis

HIGHLIGHTS

• who: Tilmann Graf from the Department of Neurology, Evangelisches Klinikum Bethel, OWL University Hospital, Bielefeld University, Bielefeld‑Bethel Campus, Bielefeld, Germany have published the paper: Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis, in the Journal: (JOURNAL) of 28/04/2021

SUMMARY

To inactivate the suspected pathogenic platelet factor-4 (PF4)-heparin antibodies through Fc receptor blocking, treatment with high-dose immunoglobulins (IVIG) at a dose . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.